Keyphrases
Tuberculosis
100%
India
76%
Multidrug-resistant Tuberculosis (MDR-TB)
76%
Tuberculosis Treatment
51%
Mumbai
50%
Drug Susceptibility Testing
49%
Mycobacterium Tuberculosis (M. tb)
46%
Pediatric Tuberculosis
37%
Tertiary Care Hospital
37%
COVID-19
37%
Tuberculosis Patients
35%
Linezolid
33%
Confidence Interval
32%
Tuberculosis Diagnosis
31%
Indian children
31%
Drug Resistance
31%
Treatment Response
30%
Pharmacokinetics
28%
HIV Infection
25%
Linezolid Resistance
25%
Whole Genome Sequencing
23%
Tuberculosis Disease
23%
Rifampin
23%
Active Tuberculosis
21%
Household Contacts
21%
Tuberculosis Regimen
20%
Body Mass Index
18%
Sputum
18%
Odds Ratio
17%
Rifampicin Resistance
16%
Public Health Priority
16%
Treatment Initiation
15%
Bolivia
15%
Chagas Disease
15%
Treatment Regimen
15%
Infectious Diseases
15%
New Regimen
15%
Tuberculosis Treatment Outcomes
14%
Bedaquiline
14%
Xpert MTB
14%
Drug Resistance mutations
13%
Delamanid
13%
Epidemiology
13%
Clinical Laboratory
13%
Fluoroquinolones
13%
Low-middle Income Countries
12%
Insured Population
12%
Tuberculous Meningitis
12%
Short Course
12%
Transcriptomics
12%
Medicine and Dentistry
Infection
57%
Multidrug Resistant Tuberculosis
52%
Mycobacterium Tuberculosis
52%
Outpatient
51%
Tertiary Care
51%
Linezolid
50%
Human Immunodeficiency Virus
50%
Disease
49%
Severe Acute Respiratory Syndrome Coronavirus 2
41%
Drug Sensitivity
36%
Diarrhea
28%
COVID-19
27%
Household
26%
Cohort Effect
26%
Sputum
25%
Next Generation Sequencing
25%
Pediatrics
25%
Human Immunodeficiency Virus Infection
25%
Drug Resistance
21%
Symptom
21%
Quinolone Derivative
21%
Tuberculosis
20%
Tuberculosis Treatment
20%
Diagnosis
20%
Body Mass Index
19%
Rifampicin
18%
Public Health
17%
Disease Burden
16%
Chagas Disease
15%
Bedaquiline
14%
Moxifloxacin
14%
Epileptic Absence
14%
Odds Ratio
14%
Patient Referral
13%
Clinical Feature
13%
Meningitis
13%
Low and Middle Income Countries
12%
Transcriptomics
12%
Rotavirus
12%
Cost-Effectiveness Analysis
12%
Chronic Disease
12%
Mycobacterium Avium-Intracellulare Infection
12%
Nervous System
12%
Plastic Surgery Procedure
12%
Drug Hypersensitivity
12%
Treatment Response
12%
Disease Course
12%
Mental Health Care
12%
Aspergillosis
12%
Coronavirinae
12%
Pharmacology, Toxicology and Pharmaceutical Science
Disease
86%
Multi-Drug-Resistant Tuberculosis
61%
HIV
48%
Infection
41%
Pharmacokinetics
39%
Coronavirinae
37%
Linezolid
37%
Symptom
34%
SARS Coronavirus
30%
Diarrhea
28%
Quinolone Derivative
26%
Bedaquiline
26%
Human Immunodeficiency Virus Infection
25%
Mycobacterium Tuberculosis
20%
Rifampicin
19%
Respiratory Tract
16%
Moxifloxacin
16%
Isoniazid Plus Rifampicin
16%
Drug Resistance
16%
Chagas Disease
15%
Epileptic Absence
14%
Vaccination Policy
14%
Clinical Feature
13%
Tuberculous Meningitis
12%
Emtricitabine
12%
Rotavirus
12%
Pretomanid
12%
Dolutegravir
12%
Chronic Disease
12%
Delamanid
12%
Disease Course
12%
Tenofovir
12%
Extensively Drug-Resistant Tuberculosis
12%
Recurrent Disease
12%
Prospective Cohort Study
12%
Myalgia
12%
Diabetes Mellitus
12%
Tenofovir Alafenamide
12%
Chagas Cardiomyopathy
12%
Prevalence
11%
Virus RNA
11%
Tuberculosis
8%
Congestive Heart Failure
6%
Obesity
6%
Drug Resistant Tuberculosis
5%
Streptomycin
5%